Novelix Pharmaceuticals Limited (formerly Trimurthi Limited) has filed mandatory disclosures under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, following the allotment of 11,50,000 equity shares through warrant conversion to promoter group entities.

Warrant Conversion and Share Allotment

The board approved the allotment of 11,50,000 equity shares with a face value of Rs. 10.00 each at an issue price of Rs. 20.00 per share, including a premium of Rs. 10.00 per share. This allotment resulted from warrant holders exercising their conversion option, with warrant holders paying the remaining 75% of the issue price (Rs. 15.00 per warrant).

The warrant conversion was part of a larger preferential issue of 15,000,000 warrants originally allotted on January 10, 2025. The warrants were issued following a special resolution passed at an Extra-Ordinary General Meeting on November 18, 2024, with in-principle approval from BSE Limited received on December 31, 2024.

SEBI Disclosure Requirements

The company has submitted detailed disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, documenting the substantial acquisition by promoter group entities. The disclosure provides comprehensive shareholding details before and after the acquisition.

Impact on Share Capital Structure

Following the allotment, the company's shareholding pattern has been significantly altered, with the combined promoter group holding increasing substantially.

Director Resignation

Concurrently, the board approved the resignation of Mr. Jivamohan Divakar Valluri (DIN: 09218013), Non-Executive Director, effective from March 30, 2026. Valluri cited pre-occupation and personal commitments as reasons for stepping down from his positions including memberships in Audit Committee and Nomination & Remuneration Committee.

Regulatory Compliance

Both the share allotment and SEBI disclosures were made in compliance with applicable regulations. The company has submitted all required documentation to BSE Limited, with the intimation signed by Venkateshwarlu Pulluru, Whole-time Director (DIN: 02076871), who also serves as Designated Partner for SRINIDHI FINE-CHEMICALS LLP.

Novelix Pharmaceuticals Limited has announced the reconstitution of its key board committees following a board meeting held on March 30, 2026, at the company's registered office in Hyderabad. The meeting, which commenced at 5:00 P.M. and concluded at 06:30 P.M., resulted in structural changes to three critical committees with immediate effect.

Committee Restructuring Details

The board approved the reconstitution of the Audit Committee, Nomination & Remuneration Committee, and Stakeholders Relationship Committee, ensuring compliance with regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Audit Committee Composition

The reconstituted Audit Committee features the following structure:

Nomination & Remuneration Committee Structure

The Nomination & Remuneration Committee maintains an identical composition to the Audit Committee:

Stakeholders Relationship Committee Formation

The Stakeholders Relationship Committee has been constituted with Sridevi Belide as Chairperson:

Regulatory Compliance

The reconstitution was conducted in accordance with Regulation 30 of SEBI (LODR) Regulations, 2015, with the company promptly notifying BSE Limited about the changes. The meeting was held at the company's registered office located at H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029.

Key Appointments

Janardhan Das Kabra, a Non-Executive Independent Director, has been appointed as Chairperson of both the Audit Committee and Nomination & Remuneration Committee. Sridevi Belide, a Non-Executive Non-Independent Director, leads the Stakeholders Relationship Committee. Mayuri Baidya serves as a member across all three committees, ensuring continuity and coordination between the various governance functions.

The changes took effect immediately from March 30, 2026, and the company has requested BSE Limited to disseminate this information through their official website for public disclosure.